Authors: N Freemantle C Cooper A DiezPerez M Gitlin H Radcliffe S Shepherd C Roux
Publish Date: 2012/07/26
Volume: 24, Issue: 1, Pages: 209-217
Abstract
Network metaanalysis techniques metaanalysis adjusted indirect comparison and mixed treatment comparison MTC allow for treatment comparisons in the absence of headtohead trials In this study conditional estimates of relative treatment efficacy derived through these techniques show important differences in the fracture risk reduction profiles of marketed pharmacologic therapies for postmenopausal osteoporosisThis study illustrates how network metaanalysis techniques metaanalysis adjusted indirect comparison and MTC can provide comparisons of the relative efficacy of postmenopausal osteoporosis therapies in the absence of comprehensive headtohead trialsSource articles were identified in MEDLINE EMBASE Cochrane Central Register of Controlled Trials CENTRAL via Wiley Interscience and Cumulative Index to Nursing and Allied Health Literature CINAHL between April 28 2009 and November 4 2009 Two reviewers identified Englishlanguage articles reporting randomized controlled trials RCTs with onlabel dosing of marketed osteoporosis agents and fracture endpoints Trial design population characteristics intervention and comparator fracture outcomes and adverse events were abstracted for analysis Primary analyses included data from RCTs with fracture endpoints Sensitivity analyses also included studies with fractures reported through adverse event reports Metaanalysis compared fracture outcomes for pharmacological therapies vs placebo fixed and random effects models adjusted indirect comparisons and MTC assessed fracture risk in postmenopausal women treated with denosumab vs other agentsUsing data from 34 studies random effects metaanalysis showed that all agents except etidronate significantly reduced the risk of new vertebral fractures compared with placebo denosumab risedronate and zoledronic acid significantly reduced the risk for nonvertebral and hip fracture while alendronate strontium ranelate and teriparatide significantly reduced the risk for nonvertebral fractures MTC showed denosumab to be more effective than strontium ranelate raloxifene alendronate and risedronate in preventing new vertebral fracturesThis study was funded by Amgen Inc NF has received research grants from Amgen Inc and has served as a consultant for Amgen Inc SanofiAventis Pfizer Wyeth and Eli Lilly CC has received consulting and lecture fees from Amgen Inc GSK Eli Lilly Novartis Servier and Alliance for Bone Health ADP has received honoraria from or consulted for Amgen Inc Novartis Eli Lilly and MSD and received research grants from the Alliance of Bone Health and Amgen Inc CR has received research grants and/or honoraria from Amgen MSD Servier Novartis and Lilly MG HR and SS are employees of and have stock ownership in Amgen Inc
Keywords: